drugset / Trial / NCT06019533

A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles

NCT06019533

Phase 3 Completed 1039 enrolled Chemo Research
NaSingle-groupOpen-labelPrevention

Summary

Multicentre, single arm phase III trial to assess the pearl index of LVDS. The trial lasts 13 cycles.The assessments include (but are not limited to) recording demographic data, pregnancy tests, gynaecological examinations, laboratory tests and a quality of life questionnaire. Adolescents will undergo DXA scans to measure bone mineral density (at selected sites only). The women will be provided with an e-diary app for their smartphone, to record IP use and vaginal bleeding.

Timeline

Start
2023-08-09
Primary completion
2025-08-01
Completion
2025-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule Other

Indications

No indication recorded.